Thoratec Issues LVAD Guidelines; WorldHeart Announces June 8 FDA Panel
This article was originally published in The Gray Sheet
Executive Summary
Thoratec expects to steadily improve infection and survival rates associated with the HeartMate XVE LVAD by issuing a series of "best practice" guidelines developed by the most experienced ventricular assist device implanters
You may also be interested in...
Arrow Contemplates Fate Of LVAD Business; WorldHeart, Thoratec Start Trials
Arrow International's board of directors will assess the future commercial potential of its left-ventricular assist devices at a meeting April 6-7
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”